First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation
Abstract Lung carcinosarcoma is acknowledged as a rare form of lung cancer. Due to its rarity, the inability to conduct large‐scale clinical trials and interventions is currently carried out based on empirical evidence. In this study, we report the case of a 73‐year‐old female patient diagnosed with...
Main Authors: | Naoya Ishibashi, Toshiharu Tabata, Ryo Nonomura, Yutaka Oshima, Takanobu Sasaki, Hideki Mitomo, Takafumi Sugawara, Motoyasu Sagawa |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-12-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.15134 |
Similar Items
-
Erlotinib: How to increase the duration of effective use of tyrosine kinase inhibitors in non-small cell lung cancer with EGFR mutation
by: E. I. Borisova, et al.
Published: (2021-08-01) -
Efficacy of durvalumab plus chemotherapy in small-cell lung cancer with Lambert-Eaton myasthenic syndrome
by: Naoya Ishibashi, et al.
Published: (2024-01-01) -
Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
by: Kazuto Nishio, MD, PhD, et al.
Published: (2021-06-01) -
Carcinosarcoma of lung
by: S Neupane, et al.
Published: (2013-03-01) -
Ramucirumab: Boon or bane
by: Priya Tiwari
Published: (2016-09-01)